First-in-Human Dose Selection and Pharmacokinetics, Safety, Tolerability, and Immunogenicity of ARGX-119, an Agonist Antibody for Human Muscle-Specific Kinase

Personalized Repetitive Transcranial Magnetic Stimulation (PrTMS®) Reduces Major Depressive Disorder (MDD) Symptom Severity